訂正
キーワード:
SGLT2 inhibitors,
appropriate use,
application of criterion,
pharmacist intervention,
prevention of severe adverse events
2017 年 43 巻 4 号 p. erratum_4
詳細
2017 年 43 巻 4 号 p. erratum_4
第43巻 第2号 93頁 引用文献 8）を次の通り訂正いたします
誤：8）Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2016-013774.
正：8）Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2012-001768.
下線が訂正した部分
